Revance Therapeutics Company Profile (NASDAQ:RVNC)

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics logoRevance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RVNC
  • CUSIP: N/A
  • Web:
  • Market Cap: $785.88 million
  • Outstanding Shares: 30,819,000
Average Prices:
  • 50 Day Moving Avg: $25.96
  • 200 Day Moving Avg: $23.68
  • 52 Week Range: $12.35 - $28.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.54
  • P/E Growth: -0.62
Sales & Book Value:
  • Annual Revenue: $300,000.00
  • Price / Sales: 2,619.62
  • Book Value: $5.24 per share
  • Price / Book: 4.87
  • EBITDA: ($89,740,000.00)
  • Net Margins: -32,936.67%
  • Return on Equity: -55.21%
  • Return on Assets: -47.75%
  • Current Ratio: 7.94%
  • Quick Ratio: 7.94%
  • Average Volume: 148,394 shs.
  • Beta: 1.64
  • Short Ratio: 23.45

Frequently Asked Questions for Revance Therapeutics (NASDAQ:RVNC)

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.93) by $0.03. The firm earned $0.08 million during the quarter, compared to analysts' expectations of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. Revance Therapeutics's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.88) earnings per share. View Revance Therapeutics' Earnings History.

Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?

4 brokerages have issued 12 month target prices for Revance Therapeutics' shares. Their predictions range from $28.00 to $50.00. On average, they expect Revance Therapeutics' share price to reach $37.00 in the next twelve months. View Analyst Ratings for Revance Therapeutics.

What are analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:

  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (10/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Today Revance announced that Mark Foley has been appointed to the Board of Directors, effective 9/5/17." (9/6/2017)

Who are some of Revance Therapeutics' key competitors?

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:

  • Angus Charles Russell, Independent Chairman of the Board
  • L. Daniel Browne, Co-Founder, President, Chief Executive Officer, Director
  • Lauren P. Silvernail, Chief Financial Officer, Chief Business Officer
  • Abhay Joshi Ph.D., Chief Operating Officer
  • Todd E. Zavodnick, Chief Commercial Officer and President, Aesthetics & Therapeutics
  • Mark J. Foley, Director
  • Robert F. Byrnes, Independent Director
  • Julian S. Gangolli, Independent Director
  • Phyllis I. Gardner M.D., Independent Director
  • Philip J. Vickers, Independent Director

How do I buy Revance Therapeutics stock?

Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of Revance Therapeutics stock can currently be purchased for approximately $25.50.

MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.00 (45.10% upside)
Consensus Price Target History for Revance Therapeutics (NASDAQ:RVNC)
Price Target History for Revance Therapeutics (NASDAQ:RVNC)
Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017Cantor FitzgeraldReiterated RatingBuy$50.00HighView Rating Details
8/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$34.00MediumView Rating Details
7/26/2017Piper Jaffray CompaniesSet Price TargetBuy$28.00LowView Rating Details
6/8/2017AegisReiterated RatingBuy$36.00MediumView Rating Details
8/5/2016Brean CapitalReiterated RatingHoldN/AView Rating Details
6/14/2016SunTrust Banks, Inc.Lower Price TargetBuy$46.00 -> $22.00N/AView Rating Details
6/14/2016GuggenheimReiterated RatingBuy$55.00N/AView Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/10/2015William BlairReiterated RatingBuy$59.00N/AView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for Revance Therapeutics (NASDAQ:RVNC)
Earnings by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Earnings History by Quarter for Revance Therapeutics (NASDAQ RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.93)($0.90)$0.05 million$0.08 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.84)($0.94)$0.07 million$0.08 millionViewListenView Earnings Details
2/27/2017Q416($0.84)($0.95)$0.07 million$0.08 millionViewListenView Earnings Details
11/3/2016Q316($0.89)($0.64)$0.08 million$0.08 millionViewN/AView Earnings Details
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 million$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)$0.15 million$0.08 millionViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)$0.15 million$0.08 millionViewListenView Earnings Details
3/2/2015($0.53)($0.60)$0.08 million$0.08 millionViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)$0.08 millionViewN/AView Earnings Details
8/12/2014($0.68)($0.69)$0.08 millionViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)$0.16 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
2017 EPS Consensus Estimate: ($3.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.85)($0.80)($0.83)
Q2 20172($0.99)($0.98)($0.99)
Q3 20172($1.02)($1.02)($1.02)
Q4 20172($0.99)($0.95)($0.97)
(Data provided by Zacks Investment Research)


Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Revance Therapeutics (NASDAQ:RVNC)
Insider Ownership Percentage: 18.86%
Institutional Ownership Percentage: 89.32%
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/18/2017L Daniel BrowneCEOSell7,662$26.16$200,437.92View SEC Filing  
10/12/2017Lauren P SilvernailCFOSell11,164$26.67$297,743.88View SEC Filing  
9/20/2017L Daniel BrowneCEOSell7,600$23.58$179,208.00View SEC Filing  
8/23/2017L Daniel BrowneCEOSell22,800$22.76$518,928.00View SEC Filing  
5/24/2017L Daniel BrowneCEOSell19,713$20.35$401,159.55View SEC Filing  
5/22/2017L Daniel BrowneCEOSell12,287$20.20$248,197.40View SEC Filing  
5/22/2017Lauren P SilvernailCFOSell1,793$20.20$36,218.60View SEC Filing  
1/25/2017L Daniel BrowneCEOSell12,000$19.78$237,360.00View SEC Filing  
12/28/2016L Daniel BrowneCEOSell12,000$20.94$251,280.00View SEC Filing  
11/25/2016L Daniel BrowneCEOSell12,000$17.92$215,040.00View SEC Filing  
10/26/2016L Daniel BrowneCEOSell12,000$14.85$178,200.00View SEC Filing  
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Revance Therapeutics (NASDAQ:RVNC)
Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
Loading headlines, please wait.



Revance Therapeutics (RVNC) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.